Total Payments
$1.2M
2024 Payments
$198,426
Companies
28
Transactions
1,424
Payment Breakdown by Category
Other$924,163 (75.8%)
Consulting$122,023 (10.0%)
Travel$119,644 (9.8%)
Food & Beverage$35,117 (2.9%)
Research$18,299 (1.5%)
Education$231.32 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $918,463 | 342 | 75.3% |
| Consulting Fee | $122,023 | 56 | 10.0% |
| Travel and Lodging | $119,644 | 477 | 9.8% |
| Food and Beverage | $35,117 | 537 | 2.9% |
| Unspecified | $18,299 | 6 | 1.5% |
| Honoraria | $5,700 | 1 | 0.5% |
| Education | $231.32 | 5 | 0.0% |
Payments by Type
General
$1.2M
1,418 transactions
Research
$18,299
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1.0M | 1,079 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $86,581 | 125 | $0 (2024) |
| Amgen Inc. | $37,735 | 44 | $0 (2023) |
| Sobi, Inc | $17,827 | 31 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $15,564 | 9 | $0 (2021) |
| Optinose US, Inc. | $12,029 | 21 | $0 (2021) |
| AstraZeneca AB | $7,548 | 2 | $0 (2019) |
| Genentech USA, Inc. | $6,381 | 15 | $0 (2024) |
| Mylan Specialty L.P. | $6,099 | 11 | $0 (2017) |
| Acerta Pharma LLC | $5,642 | 5 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $198,426 | 206 | AstraZeneca Pharmaceuticals LP ($172,541) |
| 2023 | $224,414 | 254 | AstraZeneca Pharmaceuticals LP ($178,005) |
| 2022 | $214,587 | 242 | AstraZeneca Pharmaceuticals LP ($171,707) |
| 2021 | $145,155 | 156 | AstraZeneca Pharmaceuticals LP ($124,555) |
| 2020 | $75,584 | 72 | AstraZeneca Pharmaceuticals LP ($74,378) |
| 2019 | $215,429 | 266 | AstraZeneca Pharmaceuticals LP ($171,080) |
| 2018 | $131,934 | 171 | AstraZeneca Pharmaceuticals LP ($122,760) |
| 2017 | $13,951 | 57 | AstraZeneca Pharmaceuticals LP ($6,406) |
All Payment Transactions
1,424 individual payment records from CMS Open Payments — Page 2 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $15.92 | General |
| Category: Respiratory | ||||||
| 10/28/2024 | CSL Behring | Haegarda (Biological) | Education | In-kind items and services | $60.73 | General |
| Category: Immunology | ||||||
| 10/28/2024 | CSL Behring | Haegarda (Biological) | Education | In-kind items and services | $60.73 | General |
| Category: Immunology | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Respiratory | ||||||
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Respiratory | ||||||
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $15.92 | General |
| Category: Respiratory | ||||||
| 09/30/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Respiratory | ||||||
| 09/24/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,137.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/23/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Respiratory | ||||||
| 09/23/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Respiratory | ||||||
| 09/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $1,172.12 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $541.83 | General |
| Category: Respiratory | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $207.83 | General |
| Category: Respiratory | ||||||
| 09/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $117.76 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $115.82 | General |
| Category: Respiratory | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Respiratory | ||||||
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $350.00 | General |
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $286.76 | General |
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $48.15 | General |
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $38.13 | General |
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Food and Beverage | In-kind items and services | $36.00 | General |
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Food and Beverage | In-kind items and services | $16.29 | General |
| 09/16/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY). | AstraZeneca Pharmaceuticals LP | $7,912 | 2 |
| A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. | AstraZeneca AB | $7,548 | 2 |
| Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting Beta2 Agonist BORA | AstraZeneca Pharmaceuticals LP | $2,840 | 2 |
About Dr. Michael Marcus, MD
Dr. Michael Marcus, MD is a Pediatric Allergy/Immunology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1134114192.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Marcus, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $198,426 received in 2024. These payments were reported across 1,424 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($918,463).
Ad
Practice Information
- Specialty Pediatric Allergy/Immunology
- Other Specialties Pediatric Pulmonology
- Location Brooklyn, NY
- Active Since 09/15/2005
- Last Updated 03/25/2015
- Taxonomy Code 2080P0201X
- Entity Type Individual
- NPI Number 1134114192
Products in Payments
- FASENRA (Biological) $350,324
- FASENRA (Drug) $324,935
- TEZSPIRE (Biological) $257,091
- DUPIXENT (Biological) $93,377
- SYNAGIS (Biological) $41,705
- AIRSUPRA (Drug) $17,916
- Synagis (Drug) $13,318
- Xhance (Drug) $12,029
- Xolair (Biological) $6,381
- Dymista (Drug) $6,099
- SYNAGIS (Drug) $4,510
- Odactra (Biological) $748.21
- CINRYZE (Drug) $222.21
- ALVESCO (Drug) $170.17
- Haegarda (Biological) $147.96
- SYMBICORT (Drug) $143.63
- NUCALA (Biological) $139.22
- CINQAIR (Drug) $126.39
- NIOX VERO DEVICE (Device) $109.83
- XOLAIR (Biological) $99.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.